ZA201504878B - Method for treating cancer based on mutation status of k-ras - Google Patents

Method for treating cancer based on mutation status of k-ras

Info

Publication number
ZA201504878B
ZA201504878B ZA2015/04878A ZA201504878A ZA201504878B ZA 201504878 B ZA201504878 B ZA 201504878B ZA 2015/04878 A ZA2015/04878 A ZA 2015/04878A ZA 201504878 A ZA201504878 A ZA 201504878A ZA 201504878 B ZA201504878 B ZA 201504878B
Authority
ZA
South Africa
Prior art keywords
ras
treating cancer
cancer based
mutation status
mutation
Prior art date
Application number
ZA2015/04878A
Other languages
English (en)
Inventor
Brachmann Carrie
Pierce Daniel
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of ZA201504878B publication Critical patent/ZA201504878B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA2015/04878A 2013-01-11 2015-07-07 Method for treating cancer based on mutation status of k-ras ZA201504878B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361848793P 2013-01-11 2013-01-11
US201361752417P 2013-01-14 2013-01-14
US13/794,712 US20140199405A1 (en) 2013-01-11 2013-03-11 Method for treating cancer based on mutation status of k-ras
PCT/US2014/011097 WO2014110408A1 (en) 2013-01-11 2014-01-10 Method for treating cancer based on mutation status of k-ras

Publications (1)

Publication Number Publication Date
ZA201504878B true ZA201504878B (en) 2016-10-26

Family

ID=51165319

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2015/04878A ZA201504878B (en) 2013-01-11 2015-07-07 Method for treating cancer based on mutation status of k-ras

Country Status (12)

Country Link
US (1) US20140199405A1 (enExample)
EP (1) EP2943184A4 (enExample)
JP (1) JP2016506908A (enExample)
KR (1) KR20150103746A (enExample)
AU (1) AU2014205254A1 (enExample)
BR (1) BR112015016466A2 (enExample)
CA (1) CA2897581A1 (enExample)
HK (1) HK1217292A1 (enExample)
IL (1) IL239740A0 (enExample)
MX (1) MX2015008889A (enExample)
WO (1) WO2014110408A1 (enExample)
ZA (1) ZA201504878B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT1585548T (lt) 2002-12-09 2018-09-25 Abraxis Bioscience, Llc Farmakologinių agentų kompozicijos ir įvedimo būdai
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
NZ595313A (en) 2005-02-18 2013-03-28 Abraxis Bioscience Llc The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
CA2880727C (en) 2005-08-31 2019-05-07 Neil P. Desai Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
WO2008021288A2 (en) 2006-08-11 2008-02-21 Johns Hopkins University Consensus coding sequences of human breast and colorectal cancers
CA2672618C (en) 2006-12-14 2021-03-02 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
AU2008260447B2 (en) * 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
PT2419732T (pt) 2009-04-15 2019-12-24 Abraxis Bioscience Llc Composições e métodos de nanopartículas isentas de priões
PL2552438T3 (pl) 2010-03-26 2016-12-30 Sposoby leczenia raka wątrobowokomórkowego
RU2016119999A (ru) 2010-03-29 2018-11-08 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения онкологических заболеваний
BR112012024590A2 (pt) 2010-03-29 2016-05-31 Abraxis Bioscience Inc métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos
JP6257324B2 (ja) 2010-06-04 2018-01-10 アブラクシス バイオサイエンス， エルエルシー 膵臓がんの処置方法
CA3063641A1 (en) 2011-04-28 2012-11-01 Abraxis Bioscience, Llc Intravascular delivery of nanoparticle compositions and uses thereof
SMT201900502T1 (it) 2011-12-14 2019-11-13 Abraxis Bioscience Llc Uso di eccipienti polimerici per la liofilizzazione o il congelamento di particelle
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
JP6349381B2 (ja) 2013-03-12 2018-06-27 アブラクシス バイオサイエンス， エルエルシー 肺がんを処置する方法
NZ630213A (en) 2013-03-14 2017-05-26 Abraxis Bioscience Llc Methods of treating bladder cancer
BR112016013138A2 (pt) 2013-12-09 2018-01-16 Targovax Asa mistura de peptídeos
WO2015169804A1 (en) * 2014-05-06 2015-11-12 Targovax As Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
JP6987644B2 (ja) 2015-06-29 2022-01-05 アブラクシス バイオサイエンス， エルエルシー 類上皮細胞腫瘍を処置する方法
AU2017340913A1 (en) * 2016-10-07 2019-04-18 Abraxis Bioscience, Llc Methods of treating biliary tract cancer
EP3444272A1 (en) * 2017-08-17 2019-02-20 International-Drug-Development-Biotech Treatment of ck8 positive cancers in relation with k-ras gene status
RU2020134124A (ru) 2018-03-20 2022-04-20 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи СПОСОБЫ ЛЕЧЕНИЯ НАРУШЕНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ ПУТЕМ ВВЕДЕНИЯ СОДЕРЖАЩИХ ИНГИБИТОР mTOR И АЛЬБУМИН НАНОЧАСТИЦ
WO2021086946A1 (en) 2019-10-28 2021-05-06 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin
US20230172935A1 (en) * 2020-05-08 2023-06-08 Cardiff Oncology, Inc. Methods of monitoring kras mutations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ595313A (en) * 2005-02-18 2013-03-28 Abraxis Bioscience Llc The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
EP1913157B2 (en) * 2005-06-28 2016-10-26 Genentech, Inc. Egfr and kras mutations for prediction of patient response to egfr inhibitor treatment
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
MX2009009787A (es) * 2007-03-13 2009-09-22 Amgen Inc Mutaciones de k-ras y terapia con anticuerpos anti-egfr.
WO2011116181A1 (en) * 2010-03-17 2011-09-22 Caris Life Sciences, Inc. Theranostic and diagnostic methods using sparc and hsp90
CN102573832B (zh) * 2009-08-25 2015-07-22 阿布拉科斯生物科学有限公司 利用紫杉烷和刺猬抑制剂的纳米颗粒组合物的联合治疗
RU2016119999A (ru) * 2010-03-29 2018-11-08 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения онкологических заболеваний
KR20130043104A (ko) * 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
WO2011146803A1 (en) * 2010-05-20 2011-11-24 Synta Pharmaceuticals Corp. Method of treating lung adenocarcinoma with hsp90 inhibitory compounds
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
EP3444363B1 (en) * 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CA2865335A1 (en) * 2012-03-09 2013-09-12 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods
WO2013138371A1 (en) * 2012-03-12 2013-09-19 Merrimack Pharmaceuticals, Inc. Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody

Also Published As

Publication number Publication date
IL239740A0 (en) 2015-08-31
JP2016506908A (ja) 2016-03-07
MX2015008889A (es) 2015-11-13
EP2943184A4 (en) 2016-07-20
HK1217292A1 (zh) 2017-01-06
EP2943184A1 (en) 2015-11-18
CA2897581A1 (en) 2014-07-17
AU2014205254A1 (en) 2015-07-23
WO2014110408A1 (en) 2014-07-17
US20140199405A1 (en) 2014-07-17
KR20150103746A (ko) 2015-09-11
BR112015016466A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
ZA201504878B (en) Method for treating cancer based on mutation status of k-ras
IL288181A (en) Cancer treatment methods
IL272905A (en) Methods of treating pancreatic cancer
IL304252A (en) Cancer treatment methods
IL289947A (en) A method for treating cancer
IL237791A0 (en) A method for treating cancer
IL245281A0 (en) Methods and preparations for the treatment of cancer
SG11201603050TA (en) Methods for treating cancers
SG11201503893RA (en) Method of treating cancer
IL240935A0 (en) Methods of treating lung cancer
EP3057594A4 (en) Method of treating cancer
EP2895206A4 (en) METHOD FOR TREATING CARCINOMA
SG11201508878WA (en) Methods of treating cancer
AP2015008803A0 (en) Methods for treating psoriasis using an anti-il-23antibody
IL240688A0 (en) Pancreatic cancer treatment methods
LT3016682T (lt) Vėžio gydymo būdai
EP3074040A4 (en) Method of treating cancer
ZA201507762B (en) Methods of treating cancer
PT2836176T (pt) Técnica para tratar presbiopia
AU2013904620A0 (en) Method of treating cancer
ZA201604162B (en) Method for treating sulfide-free minerals